Navigation Links
Lotus Completed R-Bambuterol's Pilot Scale Production for Clinical Trials
Date:8/3/2010

BEIJING, Aug. 3 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company"), a growing developer, manufacturer and seller of medicine and drugs in the People's Republic of China (the "PRC"), announced today that it has completed production of active pharmaceutical ingredient ("API") and tablets of R-Bambuterol for use in clinical trials according to China's State Food & Drug Administration ("SFDA")'s stringent regulations with regards to the preparation of active trial medication.

It took the Company one month to successfully design and upgrade its evaluation device. The evaluation device is now capable of detecting and analyzing purity of the enantiopure drug R-Bambuterol. It took the Company forty days to successfully upgrade the laboratory scale production to the pilot scale production, with enough API and tablets for use in clinical trials I & II.

CEO, Dr. Zhongyi Liu, commented, "R-Bambuterol is the first Class 1 new drug in our pipeline. Its preclinical studies show that, in treating asthma, it is more effective and has less side-effects than Bambuterol. Lotus has primary responsibility for R-Bambuterol's clinical research, commercialization, commercial manufacture and sales in China. We look forward to the timely launch of the new product in 2013-2014."

About Lotus Pharmaceuticals, Inc. ( http://www.lotuspharma.com )

Lotus Pharmaceuticals, Inc. is a growing developer and producer of drugs and a licensed national seller of pharmaceutical items in the PRC. Lotus operates its business through its two controlled entities: Liang Fang Pharmaceutical, Ltd. and En Ze Jia Shi Pharmaceutical, Ltd. Lotus' current drug development is focused on the treatment of cerebro-cardiovascular disease, asthma and diabetes. Liang Fang sells drugs directly and indirectly through its national sales channels to hospitals, clinics and drugs stores in 30 provinces of the PRC.

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intent," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "should," "could," "would," "may," or words or expressions of similar meaning. Such statements are not guarantees of future performance and could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including, but not limited to, changes from anticipated levels of sales, future national or regional economic and competitive and regulatory conditions, changes in relationships with customers, access to capital, increased costs, difficulties in developing and marketing new products, marketing existing products, customer acceptance of existing and new products, the time to get new drugs approved by the State Food and Drug Administration and other factors. Additional information regarding risks can be found in the Company's Annual Report on Form 10K and its other filings with the SEC. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to update the forward-looking information contained in this press release.

    For more information, please contact:

    Lotus Pharmaceuticals, Inc.
     Yan Zeng, CFO
     Tel:   +86-10-6389-9868
     Email: zy@lotuspharma.com


'/>"/>
SOURCE Lotus Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lotus Pharmaceuticals Terminates SEDA
2. Lotus Pharmaceuticals to Present at Global Hunter Securities 2010 China Conference
3. Pink Lotus Breast Center to Integrate Electronic Brachytherapy Cancer Treatment Platform
4. Lotus Pharmaceuticals, Inc. Reports Strong First Quarter 2010 Financial Results
5. Lotus Pharmaceuticals Laevo-Bambuterol Received SFDA Approval to Commence Clinical Trials
6. Lotus Pharmaceuticals to Exhibit at the 63rd PHARMCHINA
7. Lotus Pharmaceuticals Reports Groundbreaking Ceremony
8. Lotus Pharmaceuticals, Inc. Strengthens Beijing Presence with Direct Sales to Drug Stores
9. Lotus Pharmaceuticals, Inc. to Exhibit at the 62nd PHARMCHINA
10. Lotus Pharmaceuticals, Inc. Reports Third-Quarter 2009 Results
11. Lotus Pharmaceuticals, Inc.s New Drug Laevo-Bambutero Begins Evaluation for Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... Minn. , July 20, 2017  Prime Therapeutics LLC ... Jonathan Gavras , M.D., following today,s Institute for Clinical and ... report on the effectiveness and value of abuse-deterrent formulations ... on the policy roundtable at the meeting. ... not a material cost benefit to the use of abuse-deterrent ...
(Date:7/17/2017)... -- MedX Holdings, Inc., the manufacturer and global distributor of ... today announced the national roll out of its MedX ... standard for the treatment of low back injuries and ... How it works: MedX ... who prescribe the MedX Home Back Machine Program for ...
(Date:7/14/2017)... DUBLIN , July 14, 2017 Endo International plc ... results on Tuesday, August 8, 2017.  Members of its senior management ... financial markets open at 8:30 a.m. ET. The ... (866) 497-0462, International (678) 509-7598, and the passcode is 45397076. ... A replay of the ...
Breaking Medicine Technology:
(Date:7/28/2017)... ... 28, 2017 , ... The Military Family Initiative (MFI), a ... the grant recipients of its inaugural community outreach grant program. , MOAA ... Falcon’s Landing Chapter, Sterling, Va.: $5,000. Community Veterans Collaboration. , ...
(Date:7/28/2017)... ... July 28, 2017 , ... Stephen Weber, MD, is excited to ... science of Platelet Rich Plasma (PRP). Founder of Weber Facial Plastic Surgery, Dr. Weber’s ... women. Through his groundbreaking PRP procedures, Dr. Weber is quickly bringing hair loss treatment ...
(Date:7/28/2017)... , ... July 28, 2017 , ... ActivePDF, a global ... Best Places to Work in Orange County. As a multi-year recipient, ActivePDF continues to ... County, CA. , ActivePDF is known for their code-driven suite of PDF automation products, ...
(Date:7/28/2017)... ... July 28, 2017 , ... At its first ginger symposium on July 18, ... ginger industry. The funds will be used for land preparation, seed and organic farming ... budget will support both new and existing small-hold farmers and will also help strengthen ...
(Date:7/28/2017)... ... July 28, 2017 , ... Date aired: July 17th, 2017 , Guest: ... of first generation immigrants before her, Rose Hong came to America to realize a ... the part of loving parents who made sure their daughter got to the U.S. ...
Breaking Medicine News(10 mins):